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Abstract
Purpose—We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) 
events among 9679 women treated for breast cancer on four adjuvant Alliance for Clinical Trials 
in Oncology trials with >90 months of follow-up in order to better characterize the risk for 
AML/MDS in older patients receiving anthracyclines.
Methods—We used multivariable Cox regression to examine factors associated with AML/MDS, 
adjusting for age (≥65 vs. <65 years; separately for ≥70 vs. <70 years), race/ethnicity, insurance, 
performance status, and anthracycline receipt. We also examined the effect of cyclophosphamide, 
the interaction of anthracycline and age, and outcomes for those developing AML/MDS.
Results—On Cancer and Leukemia Group B (CALGB) 40101, 49907, 9344, and 9741, 7290 
received anthracyclines; 15% were in the age ≥65 and 7% were ≥70. Overall, 47 patients 
developed AML/MDS (30 AML [0.3%], 17 MDS [0.2%]); 83% of events occurred within 5 years 
of study registration. Among those age ≥65 and ≥70, 0.8 and 1.0% developed AML/MDS (vs. 
0.4% for age <65), respectively. In adjusted analyses, older age and anthracycline receipt were 
significantly associated with AML/MDS (adjusted hazard ratio [;HR] for age ≥65 [vs.<65] = 3.13, 
95% confidence interval [CI] 1.18–8.33; HR for anthracycline receipt [vs. no anthracycline] = 
5.16, 95% CI 1.47–18.19). There was no interaction between age and anthracycline use. Deaths 
occurred in 70% of those developing AML/MDS.
Conclusions—We observed an increased risk for AML/MDS for older patients and those 
receiving anthracyclines, though these events were rare. Our results help inform discussions 
surrounding anticipated toxicities of adjuvant chemotherapy in older patients.
Keywords
Breast cancer; Older patients; Leukemia; Myelodysplastic syndrome; Chemotherapy
Introduction
There are an estimated 20,830 cases of acute myeloid leukemia (AML) annually, 
representing 1.3% of all new cancer cases, with an approximate lifetime risk of 0.5–1% [1]. 
According to registry data, 14.7 women per 100,000 (0.01%) develop AML annually once 
they reach the age 65 years or older (vs. 1.8 women per 100,000 for ages <65) and the risk 
increases with age, with 20.2 women per 100,000 (0.02%) developing AML during ages 80–
84 [1, 2]. Although myelodysplastic syndrome (MDS) is also a disease of aging, the 
incidence and lifetime risk for MDS is more challenging to define because of difficulties 
and/or delays in diagnosing MDS in some patients (e.g., unexplained anemia). As a result, 
there is a range of incidence rates reported in the literature (i.e., 20–50 cases per 100,000 for 
patients age >70 per year [0.02–0.05% of patients in this age group]) [3, 4]. According to 
recent registry data, 22.3 and 42.3 cases of MDS are diagnosed annually per 100,000 U.S. 
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women ages 70–79 and ≥80, respectively [1, 5]. Collectively, a new diagnosis of AML or 
MDS occurs annually in approximately 0.16% of U.S. women in the age 60 and older, 
translating into 0.8% of women in this age group over a 5-year period [1, 2, 5].
Although serious long-term sequelae of adjuvant chemotherapy for breast cancer are rare, 
malignant hematologic complications such as AML/MDS have been consistently 
demonstrated in patients receiving anthracycline-based chemotherapy. Prior studies have 
also shown that increasing age is associated with a higher risk for both AML/MDS 
compared with younger patients receiving treatment. However, assessments of therapy-
related complications in older patients are limited by low numbers of older patients on 
studies, the small number of studies available within older populations specifically [6, 7], 
inclusion of dated adjuvant trials [7–9], or restriction to single institution [10], registry [11] 
or claims-based data [12]. Although claims-based studies are informative because of their 
large sample sizes, these analyses do not contain details on individual patient characteristics.
Up to 1% of patients have been reported to develop AML or MDS after receipt of 
anthracyclines [6–8, 12, 13], with a potential twofold increase for older (vs. younger) 
patients [7]. According to a recent report within National Comprehensive Cancer Network 
(NCCN) centers, patients receiving anthracyclines had a doubling of risk for developing a 
hematologic malignancy above baseline. In this NCCN analysis [6], the 5- and 10-year 
cumulative incidence for developing any marrow neoplasm in patients with breast cancer 
having surgery alone (i.e., baseline risk) were 0.05% (95% confidence interval [CI] 0–0.14) 
and 0.20% (95% CI 0–0.51), respectively. In contrast, those receiving trimodality therapy 
(surgery, chemotherapy, and radiation) had a 5- and 10-year incidence of 0.32% (95% CI 
0.19–0.46) and 0.51% (95% CI 0.29–0.74), respectively. However, this NCCN study only 
evaluated age thresholds of <50 and ≥50 years, included myeloproliferative diagnoses other 
than AML and MDS, and did not specifically evaluate the effect of older age or performance 
status on event rates [6].
In this study of four Alliance for Clinical Trials in Oncology adjuvant chemotherapy trials 
for breast cancer, which now have extended follow-up, we characterized the rates, timing, 
and outcomes for AML/MDS events by age and evaluated the factors associated with 
development of these malignant complications. We compared AML/MDS event rates in 
anthracycline and non-anthracyline arms of each trial and in older versus younger patients. 
In addition, we separately examined risk for AML/MDS for those age ≥65 and age ≥70 at 
study entry.
Methods
Patients and data
We pooled data from four adjuvant trials enrolling patients during 1994–2010 which 
administered an anthracycline-containing regimen in at least one treatment arm: Cancer and 
Leukemia Group B (CALGB, now part of the Alliance for Clinical Trials in Oncology) 
40101, CALGB 49907, CALGB 9344, and CALGB 9741 (N9831 was excluded because 
long-term adverse event hematologic toxicity data were not available). The agents 
administered, key eligibility and accrual dates, study sample sizes, and median follow-up 
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time for each study are shown in Table 1. Each study administered an anthracycline-
containing regimen in at least one treatment arm. Eligible patients included any woman 
enrolled on these selected adjuvant studies.
Outcomes of interest
The primary endpoint of interest was any reported outcome of AML and/or MDS at any 
time during the follow-up period for patients enrolled on all included studies. We separately 
examined the occurrence of AML, MDS, and a combined event of AML/MDS for those in 
the age ≥65 and ≥70 compared to younger trial participants (age < 65). As secondary 
endpoints, for those who developed AML or MDS, we explored (a) the time from study 
registration date to AML/MDS report, (b) vital status (alive or dead at last follow-up), and 
(c) survival time from the AML/MDS report until death or last follow-up.
Independent variables
Independent variables of interest were age, defined as age ≥65 and age ≥70, and 
anthracycline receipt (yes/no). Control variables varied by model. The base model included 
race, ethnicity, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and 
insurance status. Baseline body surface area (BSA) was initially considered as a covariate 
(as an additional marker of health status) but was not significantly associated with 
AML/MDS (p = 0.4), and was not included in models. An additional model included an 
interaction term for anthracycline*age to examine associations with AML/MDS events. A 
final model also included a variable to delineate whether a participant received anthracycline 
(as part of doxorubicin and cyclophosphamide [AC]), cyclophosphamide given without 
anthracycline (cyclophosphamide-methotrexate-5-fluorouracil [CMF]), or ‘other’ (paclitaxel 
or capecitabine monotherapy, combined as one group because of smaller sample sizes). All 
variables were categorized as per Table 2.
Statistical Analysis
Patient characteristics by age and clinical trial were compared using Chi square testing. We 
examined the overall frequency (reported as a proportion of the entire study population) of 
AML, MDS, or either event for each protocol by age ≥65 (vs. <65) and age ≥70 (vs. <70) 
and by other patient characteristics such as treatment received, BSA, and ECOG PS. Aside 
from BSA, comorbid conditions were not consistently collected and were not included. To 
better understand the timing of hematologic events and how they may relate to prior 
treatment, we examined the timing of AML and MDS reporting after study registration. 
Finally, we examined the vital status and survival time from AML/MDS reporting until 
death for women developing these events.
We then performed a series of multivariable Cox regression models [14] and competing risk 
models [15] for the outcomes of developing an AML/MDS event, first adjusting for age (≥65 
vs. <65 and separately for ≥70 vs. <70), race, ethnicity, insurance, and ECOG PS (base 
model). We then sequentially repeated models after including a variable for (a) anthracycline 
receipt (yes/no) and (b) an interaction term for age*anthracycline receipt. In a final model, 
because all patients receiving an anthracycline also received cyclophosphamide as ‘AC,’ we 
repeated models after inclusion of a categorical variable for receipt of CMF, paclitaxel, or 
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capecitabine, or AC in efforts to examine the independent effects of CMF on AML/MDS 
events.
Because this study utilized pre-existing data, Institutional Review Board exemption at Dana-
Farber Cancer Institute’s Office for Human Research Studies was granted for these analyses. 
Data collection and statistical analyses were conducted by the Alliance Statistics and Data 
Center. All analyses were based on the study databases as of December 10, 2015.
Results
Cohort characteristics
We included 9679 women enrolled on four adjuvant trials. Overall, 15% of enrolled patients 
were age ≥65 and 7% were age ≥70. Baseline characteristics for women by study and by age 
are shown in Tables 2 and 3, respectively. Overall, 7290 received anthracycline-based 
therapy on study (as part of AC, AC-paclitaxel [ACT], or sequential A-T-C), while 2374 
received capecitabine, CMF, or paclitaxel. All patients receiving anthracycline also received 
cyclophosphamide. Overall, 69 patients enrolled to trials never initiated protocol therapy and 
no AML/MDS events occurred in these patients (n = 51 from CALGB 40101, n = 10 from 
CALGB 49907, and n = 8 from CALGB 9741).
Most patients were white and had an ECOG of 0–1 when reported; the median age on 
studies ranged from 48 to 72. In comparisons of characteristics for trial participants in the 
age ≥65 vs. <65 (Table 3), older women were primarily insured by Medicare, while younger 
women were mostly privately insured. Although there were also differences for ECOG PS 
by age, approximately 53.5% of patients had missing PS, limiting comparisons. Mean BSA 
was similar by age. Comparisons for age ≥70 and <70 were similar to those shown for the 
age cut-off of 65 (data not presented).
AML and MDS events
Overall, 30 cases of AML (0.3%) and 17 cases of MDS (0.2%) were reported across all four 
studies. Unadjusted results by patient characteristics and treatments received are shown in 
Table 4. Approximately, 0.2–0.4% of those receiving an anthracycline as part of their 
treatment regimen developed AML or MDS compared with 0–0.7% of those receiving non-
anthracycline-based regimens (of note the 0.7% was based on 1 patient [of 134] who 
received CMF). All patients in this analysis who received anthracycline also received 
cyclophosphamide as ‘AC’ and 46 of 47 women who developed AML/MDS received 
cyclophosphamide.
In unadjusted comparisons by age, 0.4 and 0.4% of patients in the age ≥65 developed AML 
and MDS, respectively, compared with 0.3 and 0.1% of patients who aged <65. In 
comparisons using an age cut-off of 70 years old, 0.3 and 0.7% of those who aged ≥70 
developed AML and MDS, respectively, compared with 0.3 and 0.1% of those who aged 
<70 (data not shown). Unadjusted comparisons by age were not significant for the 
development of AML for either age cut-off, but were significant for both age cut-offs for 
MDS (p = 0.018 for age ≥65 and p = 0.0004 for age ≥70, data not shown).
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In the adjusted base model, age was the only variable significantly associated with 
AML/MDS (adjusted hazard ratio [HR] 2.86 for age ≥65 [vs. age <65], 95% CI 1.08–7.70). 
After anthracycline receipt was added to the model (Table 4, right column), the HR for age 
≥65 [vs. <65] = 3.13, 95% CI 1.18–8.33, similar to the base model, and the HR for 
anthracycline receipt was 5.16 (95% CI 1.47–18.19). The interaction term for 
anthracycline*age was not significant (p = 0.98), and it was removed from the final model. 
No other variables were significantly associated with the combined event of AML/MDS.
After addition of the categorical variable for CMF/AC/other to the base model, receiving 
‘other’ chemotherapy (vs. AC) was significantly associated with a lower probability for 
AML/MDS (adjusted HR 0.07, 95% CI 0.01–0.55), but receipt of CMF was not significantly 
different from AC (adjusted HR 1.55, 95% CI 0.32–7.52).
The results for models using age 70 as a cut-off were similar to those reported for a 
threshold of age 65, with an adjusted HR for AML/MDS for age ≥70 [vs. age <70] = 3.44 
(95% 1.18–10.0) in the models containing anthracycline (full model results not shown).
Time to AML and MDS events
The time-to-report of AML/MDS event rates by regimen is displayed in Table 5. Among 
those developing AML (n = 30), the median time-to-event was 1.65, 2.48, and 7.26 years 
after study registration for patients treated with AC, ACT, and CMF-treated patients, 
respectively (overall range 0.79–12.52 years). For MDS cases (n = 17), the median time-to-
event was 2.74, 3.23, 2.22, and 5.87 years for those receiving AC, ACT, capecitabine, and 
CMF, respectively (overall range 0.29–7.84 years).
At last known follow-up, deaths had occurred in 33 of the 47 (70%) patients who developed 
AML or MDS (Supplemental Table). For those with AML specifically, deaths had occurred 
in 22 of 30 (73%) patients, with a median time-from-AML-report-to-death of 0.05 years (19 
days) for the 11 women who received AC (range 0–3.68 years), 0.75 years for the 10 who 
received ACT (range 0.51–1.58 years), and 0.63 years for the 1 patient who received CMF. 
Among the 17 women who developed MDS, 11 (65%) deaths have been reported, with a 
median time-from-MDS report-to-death of 0.76 years for those receiving AC (n = 5) (range 
0.20–3.67 years), 1.62 years for those who received ACT (n = 4) (range 0.39–2.71 years), 
0.85 years for the patients who received capecitabine, and 1.28 years for the patients who 
received CMF.
Discussion
In this analysis of 9679 women with breast cancer receiving chemotherapy treatment on 
adjuvant Alliance protocols with over 90 months of follow-up, 30 cases of AML (0.3% 
patients) and 17 cases of MDS (0.2% of patients) have been reported to date. Among those 
who aged ≥65 and ≥70 who received chemotherapy on study, 0.8% (0.4% AML, 0.4% 
MDS) and 1.0% (0.3% AML, 1.7 % MDS) developed either AML or MDS, respectively, 
which is higher than what was observed in patients age<65 (0.3% developed AML, 0.1% 
developed MDS).
Freedman et al. Page 6
Breast Cancer Res Treat. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In adjusted models, older age and anthracyline were the only factors significantly associated 
with these events; however, there was no significant interaction for age and anthracycline 
use. All but 8 AML/MDS events (83%) occurred within 5 years of protocol registration, the 
time-frame that has typically been described for anthracycline-associated hematological 
malignant events, though a risk for later events has also been recognized [6, 7], and was also 
observed in our analysis for a small proportion of patients. Unfortunately, 70% of those 
developing AML/MDS died from these complications, often with a survival of less than one 
year, further emphasizing the seriousness of these events when they occur.
Reassuringly, our findings reflect the rarity of AML and MDS events for all women who 
were treated on study and who are typically expected to derive a 20–30% risk reduction for 
breast cancer mortality with adjuvant chemotherapy [16–18]. Our findings also suggest that 
age and anthracyclines may have independent effects on risk. Further, we would argue that 
the rates of AML observed in our study are not dissimilar from the incidence of AML [5] or 
MDS [2] observed in the general, aging population over a 5-year (60 months) time period 
(0.8% in those age ≥60 and higher risk with increasing age), where age itself is a dominant 
risk factor for hematologic malignancy. However, we acknowledge that isolating the impact 
of anthracycline receipt and its effect on age in studies such as ours is difficult because of 
the lack of a true ‘control’ group, the higher underlying risk for AML and MDS with 
increasing age as mentioned above, the fact that patients on study were likely healthier than 
the general population (because of eligibility requirements), and because of the co-
administration of cyclophosphamide, which has also been shown to increase risk [19]. In our 
analysis, 46 of 47 patients who developed AML or MDS events had cyclophosphamide 
exposure, though it is important to note that the doses of cyclophosphamide typically used in 
adjuvant breast cancer have not traditionally been associated with higher hematologic 
malignancy risk [19, 20]. In attempts to explore the independent effect of cyclophosphamide 
further, we repeated analyses after including a variable for AC/CMF/other and found that 
receipt of paclitaxel or capecitabine was associated with lower risk of AML/MDS than AC, 
but results for CMF vs. AC had a wide confidence interval and have limited interpretability.
Although older patients with breast cancer receiving adjuvant chemotherapy derive the same 
breast cancer mortality benefit as younger women [8, 17, 18, 21], concerns for treatment-
related toxicity and functional decline likely result in under-treatment of many women. 
Prospective studies have identified predictors of acute chemotherapy-related toxicity among 
older adults such as hearing loss, fall risk, social activity, and functional limitations in 
addition to previously described clinical factors and laboratory abnormalities [22, 23]. These 
studies nicely provide information to help predict for acute toxicity and powerfully inform 
decisions about administering chemotherapy; however, they do not provide guidance 
regarding the risk for longer-term toxicity, particularly patients’ susceptibility to develop 
rare complications such as AML or MDS. Further insight into the genomic and clinical 
factors associated with these serious complications is challenging but worthwhile and will 
likely require pooled serum and/or tissue-based analyses within large cohorts of patients in 
order to better understand predisposition for these rare events.
Our data confirm prior reports [6, 7, 9–12, 19, 20] that hematologic malignancies are rare in 
older patients receiving standard chemotherapy regimens, including anthracyclines. 
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However, these serious complications do occur, should be included in discussions about the 
anticipated benefits and risks of treatment, and should be described in the context of the 
underlying risk of AML and MDS with increasing age. The likelihood of developing 
AML/MDS should not limit the use of adjuvant chemotherapy regimens that include 
anthracyclines where breast cancer recurrence and mortality benefits are expected to be 
substantial, but should provide pause when chemotherapy benefits are marginal or uncertain.
Using pooled data from modern adjuvant chemotherapy protocols with extended follow-up 
for nearly 10,000 patients provides a powerful resource to study outcomes in smaller 
subgroups (e.g., older patients), and our results meaningfully add to the limited availability 
of literature about the risks for AML and MDS in older patients receiving anthracycline-
based chemotherapy regimens. However, we acknowledge several study limitations. First, 
these are secondary analyses of previously collected data with varying follow-up and 
treatments. Second, there is no ‘control’ arm of patients who did not receive chemotherapy 
and we did not have consistent information on radiation receipt, comorbidity, or growth 
factor use, precluding inclusion in models. Third, these patients represent a selected group of 
patients receiving chemotherapy on Alliance protocols and may not be generalizable to all 
older patients with breast cancer. However, the regimens administered on these trials are 
standard agents used frequently in clinical practice. Fourth, AML/MDS events were rare, 
possibly limiting our ability to detect associations with clinical and patient factors. Fifth, 
because the capture of AML/MDS events and time-to-events relied on the accuracy of data 
previously captured during long-term follow-up for individual trials, it is possible that some 
event dates were not accurate due to delays in adverse event reporting. Sixth, we did not 
have access to detailed medical records or cytogenetics of the AML/MDS cases that 
occurred, limiting some of the interpretability of what might have been treatment-related or 
not. Finally, we recognize that there were competing causes of death for women in this 
cohort and it is possible that some women died from breast cancer (or other causes) before 
their AML/MDS would have been diagnosed.
In summary, we demonstrated a small but increased risk for AML/MDS for older versus 
younger patients receiving chemotherapy and in those receiving anthracyclines but without a 
clear interaction of treatment and age. These data can be used in discussions with patients 
and can further inform decisions regarding anthracycline-based chemotherapy safety, 
particularly for older patients, where prospective data on serious toxicities are limited.
Supplementary Material
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Table 2
Patient characteristics by trial (n = 9679)
Characteristic Study
40101
(N = 3871)
49907
(N = 633)
9344
(N = 3170)
9741
(N = 2005)
Total
(N = 9679)
p value
Age at study entry (years)
<0.0001a
  N 3871 633 3170 2005 9679
 Mean (standard deviation) 52.8 (9.6) 72.0 (4.8) 47.8 (9.8) 49.9 (9.8) 51.8 (11.1)
 Range 22.0–84.0 65.0–89.0 23.0–81.0 25.0–79.0 22.0–89.0
Age group (years)
<0.0001b
 <65 3403 (87.9%) 0 (0.0%) 2988 (94.3%) 1843 (91.9%) 8234 (85.1%)
 ≥65 468 (12.1%) 633 (100.0%) 182 (5.7%) 162 (8.1%) 1445 (14.9%)
Age group
<0.0001b
 <70 3694 (95.4%) 218 (34.4%) 3115 (98.3%) 1951 (97.3%) 8978 (92.8%)
 ≥70 177 (4.6%) 415 (65.6%) 55 (1.7%) 54 (2.7%) 701 (7.2%)
Race
<0.0001b
 White 3242 (83.8%) 538 (85.0%) 2653 (83.7%) 1652 (82.4%) 8085 (83.5%)
 Black 417 (10.8%) 72 (11.4%) 298 (9.4%) 218 (10.9%) 1005 (10.4%)
 Asian/Hawaiian/American Indian/
  Indian Subcontinent
108 (2.8%) 10 (1.6%) 68 (2.1%) 39 (1.9%) 225 (2.3%)
 Other/missing/unknown/Hispanic American 104 (2.7%) 13 (2.1%) 151 (4.8%) 96 (4.8%) 364 (3.8%)
Ethnicity 0.0619b
 Hispanic/Latino 206 (5.3%) 30 (4.7%) 132 (4.2%) 81 (4.0%) 449 (4.6%)
 Non-Hispanic/not reported/unknown 3665 (94.7%) 603 (95.3%) 3038 (95.8%) 1924 (96.0%) 9230 (95.4%)
ECOG performance status
<0.0001b
 0 3441 (88.9%) 457 (72.2%) 0 (0.0%) 0 (0.0%) 3898 (40.3%)
 1 430 (11.1%) 161 (25.4%) 0 (0.0%) 0 (0.0%) 591 (6.1%)
 2 0 (0.0%) 15 (2.4%) 0 (0.0%) 0 (0.0%) 15 (0.2%)
 Missing 0 (0.0%) 0 (0.0%) 3170
 (100.0%)
2005
 (100.0%)
5175 (53.5%)
Insurance
<0.0001b
 Private 2684 (69.3%) 67 (10.6%) 2484 (78.4%) 1611 (80.3%) 6846 (70.7%)
 Medicaid based 366 (9.5%) 40 (6.3%) 195 (6.2%) 97 (4.8%) 698 (7.2%)
 Medicare/military/vet sponsored 572 (14.8%) 459 (72.5%) 209 (6.6%) 154 (7.7%) 1394 (14.4%)
 Other/missing 249 (6.4%) 67 (10.6%) 282 (8.9%) 143 (7.1%) 741 (7.7%)
Body surface areac <0.0001a
  N 3832 632 3147 1948 9559
 Mean (standard deviation) 1.9 (0.2) 1.8 (0.2) 1.8 (0.2) 1.8 (0.2) 1.8 (0.2)
 Median 1.9 1.8 1.8 1.8 1.8
 Q1, Q3 1.7, 2.0 1.7, 2.0 1.7, 1.9 1.7, 1.9 1.7, 2.0
Breast Cancer Res Treat. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Freedman et al. Page 13
Characteristic Study
40101
(N = 3871)
49907
(N = 633)
9344
(N = 3170)
9741
(N = 2005)
Total
(N = 9679)
p value
 Range 1.0–3.1 1.3–2.7 1.1–2.8 1.2–5.0 1.0–5.0
Estrogen receptor status
<0.0001b
 Negative 1298 (33.5%) 214 (33.8%) 1276 (40.3%) 668 (33.3%) 3456 (35.7%)
 Positive 2564 (66.2%) 417 (65.9%) 1871 (59.0%) 1283 (64.0%) 6135 (63.4%)
 Missing 9 (0.2%) 2 (0.3%) 23 (0.7%) 54 (2.7%) 88 (0.9%)
Progesterone receptor status
<0.0001b
 Negative 1681 (43.4%) 296 (46.8%) 1364 (43.0%) 826 (41.2%) 4167 (43.1%)
 Positive 2175 (56.2%) 333 (52.6%) 1771 (55.9%) 1116 (55.7%) 5395 (55.7%)
 Missing 15 (0.4%) 4 (0.6%) 35 (1.1%) 63 (3.1%) 117 (1.2%)
Human epidermal growth factor receptor 2
 status <0.0001
b
 Negative 3017 (77.9%) 528 (83.4%) 0 (0.0%) 0 (0.0%) 3545 (36.6%)
 Positive 719 (18.6%) 76 (12.0%) 0 (0.0%) 0 (0.0%) 795 (8.2%)
 Not done/unknown/missing 135 (3.5%) 29 (4.6%) 3170
 (100.0%)
2005
 (100.0%)
5339 (55.2%)
Because of rounding, percentages may not total 100
ECOG Eastern Cooperative Oncology Group
a
By Kruskal Wallis testing
b
By Chi square testing
c
Body surface area is reported for those with available data only (n = 9559) and 1 additional patient had a value of 5 which was counted as missing
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Table 3
Baseline patient characteristics for all trials by age (n = 9679)
Age at study entry (years)
Characteristic <65
(N = 8234)
≥65
(N = 1445)
Total
(N = 9679)
p value
Race 0.0234b
 White 6838 (83.0%) 1247 (86.3%) 8085 (83.5%)
 Black 879 (10.7%) 126 (8.7%) 1005 (10.4%)
 Asian/Hawaiian/American Indian/Indian Subcontinent 198 (2.4%) 27 (1.9%) 225 (2.3%)
 Other/missing/unknown/Hispanic American 319 (3.9%) 45 (3.1%) 364 (3.8%)
Ethnicity 0.5845b
 Hispanic/Latino 386 (4.7%) 63 (4.4%) 449 (4.6%)
 Non-Hispanic/not reported/unknown 7848 (95.3%) 1382 (95.6%) 9230 (95.4%)
ECOG performance status
<0.0001b
 0 3047 (37.0%) 851 (58.9%) 3898 (40.3%)
 1 356 (4.3%) 235 (16.3%) 591 (6.1%)
 2 0 (0.0%) 15 (1.0%) 15 (0.2%)
 Missing 4831 (58.7%) 344 (23.8%) 5175 (53.5%)
Insurance
<0.0001b
 Private 6630 (80.5%) 216 (14.9%) 6846 (70.7%)
 Medicaid based 615 (7.5%) 83 (5.7%) 698 (7.2%)
 Medicare/military/vet sponsored 331 (4.0%) 1063 (73.6%) 1394 (14.4%)
 Other/missing 658 (8.0%) 83 (5.7%) 741 (7.7%)
Body surface areaa 0.3748c
  N 8122 1437 9559
 Mean (standard deviation) 1.8 (0.2) 1.8 (0.2) 1.8 (0.2)
 Median 1.8 1.8 1.8
 Q1, Q3 1.7, 2.0 1.7, 2.0 1.7, 2.0
 Range 1.0–5.0 1.3–2.7 1.0–5.0
Estrogen receptor status 0.0177b
 Negative 2949 (35.8%) 507 (35.1%) 3456 (35.7%)
 Positive 5201 (63.2%) 934 (64.6%) 6135 (63.4%)
 Missing 84 (1.0%) 4 (0.3%) 88 (0.9%)
Progesterone receptor status 0.0004b
 Negative 3487 (42.3%) 680 (47.1%) 4167 (43.1%)
 Positive 4638 (56.3%) 757 (52.4%) 5395 (55.7%)
 Missing 109 (1.3%) 8 (0.6%) 117 (1.2%)
Human epidermal growth factor 2 status
<0.0001b
 Negative 2662 (32.3%) 883 (61.1%) 3545 (36.6%)
 Not done/unknown/missing 4952 (60.1%) 387 (26.8%) 5339 (55.2%)
Breast Cancer Res Treat. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Freedman et al. Page 15
Age at study entry (years)
Characteristic <65
(N = 8234)
≥65
(N = 1445)
Total
(N = 9679)
p value
 Positive 620 (7.5%) 175 (12.1%) 795 (8.2%)
Anthracycline received
<0.0001b
 No 1705 (20.7%) 669 (46.3%) 2374 (24.5%)
 Yes 6529 (79.3%) 761 (52.7%) 7290 (75.3%)
 Missing 0 (0.0%) 15 (1.0%) 15 (0.2%)
Cyclophosphamide received
<0.0001b
 No 1705 (20.7%) 535 (37.0%) 2240 (23.1%)
 Yes 6529 (79.3%) 895 (61.9%) 7424 (76.7%)
 Missing 0 (0.0%) 15 (1.0%) 15 (0.2%)
CMF received
 No 8234 (100%) 1311 (90.7%) 9545 (98.6%)
 Yes 0 (0%) 134 (9.3%) 134 (1.4%)
Paclitaxel or capecitabine only received
 No 6529 (79.3%) 910 (63.0%) 7439 (76.9%) <0.0001
 Yes 1705 (20.7%) 535 (37.0%) 2240 (23.1%)
Because of rounding, percentages may not total 100
ECOG Eastern Cooperative Oncology Group
a
Body surface area is reported for those with available data only (n = 9559)
b
By Chi Square testing
c
By Kruskal Wallis testing
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Table 4
Unadjusted proportions of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) by relevant 
patient characteristics (left columns) and the adjusted hazard ratio (HR) of AML and MDS as a combined 
endpoint (right column)
Characteristic Unadjusted incidence of
AML (n, %) p value
a Unadjusted incidence of
MDS (n, %)
p-
valuea
Adjusted HR for AML/
MDS (95% CI)b
Age (years) 0.435 0.018
 ≥65 6 (0.4) 6 (0.4) Reference
 <65 24 (0.3) 11 (0.1) 3.13 (1.18–8.33)
Anthracycline received 0.025 0.464
 No 1 (0.0) 2 (0.1) Reference
 Yes 29 (0.4) 15 (0.2) 5.16 (1.47–18.19)
Type of chemotherapy received 0.078 0.233 –
 AC 16 (0.4) 7 (0.2)
 ACT 13 (0.4) 8 (0.2)
 Capecitabine 0 (0) 1 (0.3)
 CMFc 1 (0.7) 1 (0.7)
 Paclitaxel 0 (0) 0 (0)
CALGB protocol 0.506 0.215 –
 40101 8 (0.2) 4 (0.1)
 49907 2 (0.3) 3 (0.5)
 9344 12 (0.4) 6 (0.2)
 9741 8 (0.4) 4 (0.2)
Baseline ECOG PS <0.0001 0.974
 0 9 (0.2) 6 (0.2) Reference
 1 0 (0) 1 (0.2) 0.73 (0.16–3.28)d
 2 1 (6.7) 0 (0) –
 Missing 20 (0.4) 10 (0.2) 1.23 (0.60–2.53)
Race 0.475 0.400
 White 28 (0.3) 15 (0.2) Reference
 Other/missing/unknown/Hispanic 1 (0.3) 1 (0.3) 0.34 (0.05–2.24)
 American 0 (0.0) 1 (0.4) 0.84 (0.11–6.18)
 Asian/Hawaiian/American Indian/
  Indian subcontinent
1 (0.1) 0 (0.0) 0.20 (0.03–1.44)
 Black
Ethnicity 0.162 0.807
 Non-Hispanic 27 (0.3) 16 (0.2) Reference
 Hispanic 3 (0.7) 1 (0.2) 2.92 (0.68–12.56)
Insurance 0.889 0.263
 Private 20 (0.3) 9 (0.1) Reference
 Medicaid 3 (0.4) 2 (0.3) 2.08 (0.74–5.90)
 Medicare/military/vet sponsor 4 (0.3) 5 (0.4) 1.00 (0.34–2.98)
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Characteristic Unadjusted incidence of
AML (n, %) p value
a Unadjusted incidence of
MDS (n, %)
p-
valuea
Adjusted HR for AML/
MDS (95% CI)b
 Other/missing 3 (0.4) 1 (0.1) 1.47 (0.49–4.42)
CALGB Cancer and Leukemia Group B, ECOG PS Eastern Cooperative Oncology Group Performance Status, AC doxorubicin and 
cyclophosphamide, CMF cyclophosphamide, methotrexate, 5-fluorouracil, T paclitaxel
aUnadjusted comparisons using Chi square testing; bolded results have p < 0.05
bAdjusted Cox proportional hazards model results, adjusting for age <65 versus ≥65, anthracycline received (yes/no), ECOG PS, race, ethnicity, 
and insurance. Bolded results are significant
cOne patient received CM only and was categorized as CMF
d
ECOG PS 1 and 2 were combined into one category for the model due to low numbers of patients with ECOG PS = 2
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Table 5
Time from study registration to report of acute myeloid leukemia (AML) and myelodysplastic syndrome 
(MDS) by chemotherapy regimen received
Chemotherapy regimen n Median (mean)
Years to AMLa
Min Max Standard deviation
AML events (n = 30)
 AC 16 1.65 (2.67) 0.79 12.52 0.74
 ACTb 13 2.48 (2.78) 0.88 6.98 0.44
 CMF 1 7.26 (7.26) 7.26 7.26 –
MDS events (n = 17)
 AC 7 2.74 (3.95) 2.03 7.84 0.83
 ACTb 8 3.23 (3.47) 0.29 7.16 0.82
 Capecitabine 1 2.22 (2.22) 2.22 2.22 –
 CMF 1 5.87 (5.87) 5.87 5.87 –
AC doxorubicin and cyclophosphamide, ACT AC-paclitaxel, CMF cyclophosphamide, methotrexate, 5-fluorouracil
a
From study registration
b
Including all schedules of administration
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